CORRECTION article

Front. Pharmacol., 07 October 2021

Sec. Experimental Pharmacology and Drug Discovery

Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.777914

Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice

  • YA

    Yongqiang Ai 1

  • WS

    Wei Shi 1

  • XZ

    Xiaobin Zuo 1

  • XS

    Xiaoming Sun 1

  • YC

    Yuanyuan Chen 1

  • ZW

    Zhilei Wang 1

  • RL

    Ruisheng Li 2

  • XS

    Xueai Song 3

  • WD

    Wenzhang Dai 1

  • WM

    Wenqing Mu 1

  • KD

    Kaixin Ding 1

  • ZL

    Zhiyong Li 1

  • QL

    Qiang Li 1

  • XX

    Xiaohe Xiao 1,3*

  • XZ

    Xiaoyan Zhan 1,3*

  • ZB

    Zhaofang Bai 1,3*

  • 1. Department of Hepatology, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China

  • 2. Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China

  • 3. China Military Institute of Chinese Materia, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China

Article metrics

View details

2

Citations

1,3k

Views

751

Downloads

In the original article, there was a mistake in Figure 5 as published. The symbols (*, **, ***, ns) of statistic differences in Figures 5B–F were wrongly labeled. The wrongly labeled Figure 5 was uploaded by accident when submitting the corrections of proof. The corrected Figure 5 appears below.

FIGURE 5

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

schisandrol B, wedelolactone, hepatic fibrosis, combined pharmacotherapy, TGF-β1/Smads signaling pathway

Citation

Ai Y, Shi W, Zuo X, Sun X, Chen Y, Wang Z, Li R, Song X, Dai W, Mu W, Ding K, Li Z, Li Q, Xiao X, Zhan X and Bai Z (2021) Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis via Modulating Multiple Signaling Pathways in Mice. Front. Pharmacol. 12:777914. doi: 10.3389/fphar.2021.777914

Received

16 September 2021

Accepted

21 September 2021

Published

07 October 2021

Volume

12 - 2021

Edited and reviewed by

Salvatore Salomone, University of Catania, Italy

Updates

Copyright

*Correspondence: Zhaofang Bai, ; Xiaoyan Zhan, ; Xiaohe Xiao,

†These authors have contributed equally to this work

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics